TEVA: Quantifying the Impact of Increased Competition
Teva Pharmaceutical Industries is down ~60% year-to-date amid competitive concerns surrounding its portfolio of drugs. Competitive concerns have largely been focused on two areas: the company’s Generic Medicines segment and the company’s Multiple Sclerosis drug, Copaxone. A closer look at the size of the revisions and investor growth expectations provides a justification for the poor stock performance for the year.